Targeting a specific enzyme to improve treatment for triple-negative breast cancer
Molecular basis and targeting of FASN in expanding PARPi utility for TNBC
['FUNDING_R01'] · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · NIH-11050720
This study is looking at how a protein called fatty acid synthase (FASN) affects triple-negative breast cancer and whether blocking it can help make treatments like PARP inhibitors work better, with the hope of finding safer and more effective options for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS (nih funded) |
| Locations | 1 site (TOLEDO, UNITED STATES) |
| Trial ID | NIH-11050720 on ClinicalTrials.gov |
What this research studies
This research investigates the role of fatty acid synthase (FASN) in triple-negative breast cancer (TNBC) and how it may influence the effectiveness of PARP inhibitors, which are currently used for treating certain breast cancers. The study aims to understand how inhibiting FASN can induce cancer cell death while sparing normal cells, potentially leading to better treatment options for patients with TNBC. By exploring the molecular mechanisms behind FASN's role in DNA repair and cancer cell survival, the research seeks to develop targeted therapies that could enhance the efficacy of existing treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer, particularly those who have not responded well to current treatments.
Not a fit: Patients with non-breast cancers or those whose breast cancer is not triple-negative may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic strategy for patients with triple-negative breast cancer, improving their treatment outcomes and reducing reliance on ineffective chemotherapies.
How similar studies have performed: Other research has shown promising results in targeting metabolic pathways in cancer cells, suggesting that this approach could be effective, although the specific targeting of FASN in TNBC is still being explored.
Where this research is happening
TOLEDO, UNITED STATES
- UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS — TOLEDO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHANG, JIAN-TING — UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS
- Study coordinator: ZHANG, JIAN-TING
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy